本报讯（记者孙杰）今天，首都医科大学三博脑科东坝新院区正式开诊。 三博脑科医院于2004年由一批神经外科专家参与创建而成，是一家集医疗、教学、科研为一体的学院型 医院。东坝新院区位于朝阳区东坝中路36号1号楼，地铁3号线东坝南站出站即到。医院总建筑面积6.3 万平方米，共设置480张床位，13间手术间，并配备复合手术室及术中核磁共振等大型设备。 记者在新院区看到，新院区整洁明亮，各项医疗服务功能完善。以中间的门诊大厅为界，院区分为南北 两楼，北楼主要是神经肿瘤、特需病房和研究型病房；南楼主要是功能神经外科、脑血管病、小儿神经 外科、脊柱脊髓外科及骨科等。 新院区预计年门诊量将超10万人次，此次新引进多台大型设备，并采用智能化技术提升医疗服务体验。 比如，门诊药房采用智能机器人分拣药品，并通过传送带送至药房窗口。每个处方的药品从分拣到窗 口，大约仅需15秒钟就可完成。 ...

Core Viewpoint - The company Sanbo Brain Science (301293.SZ) is relocating its hospital to a new site, with operations commencing on January 26 at 8:00 AM [1] Company Overview - Sanbo Brain Science was founded by experts in neurology and medical management, including renowned figures such as Luan Guoming, Yu Chunjiang, Shi Xiangen, and Zhang Yang [1] - The company has developed into a specialized chain group focusing on neurological diseases over more than 20 years, establishing itself as a leader in the neurology specialty field in China [1]

Core Viewpoint - The new East Ba District branch of Capital Medical University Sanbo Brain Hospital is set to officially open on January 26, enhancing regional medical resources and services [1][8]. Group 1: Hospital Overview - The new hospital is located at No. 36 East Ba Middle Road, Chaoyang District, with a total construction area of 63,000 square meters, featuring 480 beds and 13 operating rooms, including advanced surgical facilities [5][12]. - The hospital aims to serve over 100,000 outpatient visits annually, utilizing smart technology to improve patient experience, such as a robotic pharmacy that can sort and deliver medications in approximately 15 seconds [12][14]. Group 2: Services and Specializations - The hospital is designed as a "large specialty, small comprehensive" facility, focusing on neurology while also developing emergency, pediatric neurology, critical care, pain management, rehabilitation, and traditional Chinese medicine departments [16][19]. - The hospital will establish five centers: International Neurological Consultation Center, Brain Health Management Center, Difficult Critical Illness Diagnosis Center, High-end Talent Training Center, and Medical Achievement Transformation Center [19]. Group 3: Community Impact - The East Ba District has a dense population, and the new hospital is expected to meet the local demand for accessible healthcare services, with residents expressing anticipation for its opening [16][19]. - The hospital's strategic location and expanded services aim to address the diverse medical needs of the surrounding community [16][19].

Investment Rating - The industry rating is "Outperform the Market," indicating that the overall return of the industry is expected to exceed the market benchmark index by more than 5% over the next 6 months [14]. Core Insights - A breakthrough in Alzheimer's treatment was observed when a focused ultrasound surgery unexpectedly improved the cognitive function of a patient, challenging the traditional belief that Alzheimer's is irreversible. This condition affects nearly 17 million patients in China, leading to significant caregiving burdens [4][5]. - The research team led by Professor Sun Bomin is exploring a new approach using high-energy ultrasound to directly stimulate brain neural circuits, with initial clinical trials showing an average improvement rate of about 50% among seven moderate to severe patients [5]. - The global brain-computer interface (BCI) market is projected to grow rapidly, with an estimated size of approximately $2.62 billion in 2024, reaching $2.94 billion in 2025, and potentially growing to $12.4 billion by 2034, reflecting a compound annual growth rate of 17.35% over the next decade [6]. Summary by Sections Industry Overview - The report highlights the significant unmet medical need in Alzheimer's treatment and the potential for innovative therapies to emerge from recent clinical findings [4][5]. Market Potential - The brain-computer interface market is expected to see substantial growth, with specific projections for both global and Chinese markets, indicating a strategic focus on high-tech industries as outlined in national economic plans [6]. Investment Recommendations - The report suggests monitoring companies such as Yanshan Technology, Hanwei Technology, Sanbo Brain Science, and others, which are positioned to benefit from advancements in the BCI and related technologies [6].

Core Viewpoint - The medical services sector experienced a rise of 1.19% on January 23, with notable gains from companies like Nuohua Zhiyuan, which led the sector's performance [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4136.16, up 0.33%, while the Shenzhen Component Index closed at 14439.66, up 0.79% [1]. - The medical services sector saw significant individual stock movements, with Nuohua Zhiyuan (688315) closing at 17.00, up 13.26%, and Hai Te Biological (300683) closing at 33.31, up 7.66% [1]. Group 2: Trading Volume and Value - Nuohua Zhiyuan had a trading volume of 219,500 shares and a transaction value of 365 million yuan [1]. - Hai Te Biological recorded a trading volume of 190,900 shares with a transaction value of 632 million yuan [1]. Group 3: Capital Flow - The medical services sector saw a net inflow of 999.1 million yuan from institutional investors, while retail investors experienced a net outflow of 1.069 billion yuan [2]. - The capital flow data indicates that major stocks like Diyan Diagnosis (300244) had a net inflow of 288 million yuan from institutional investors [3].

Market Overview - The Shanghai Composite Index rose by 0.14% on January 22, with 22 out of the 28 sectors in the Shenwan classification experiencing gains, led by the construction materials and defense industries, which increased by 4.09% and 3.23% respectively [1] - The beauty and banking sectors saw the largest declines, with decreases of 0.76% and 0.43% respectively [1] Capital Flow Analysis - The main capital outflow from the two markets totaled 21.612 billion yuan, with 12 sectors experiencing net inflows [1] - The telecommunications sector had the highest net inflow, amounting to 8.019 billion yuan, and it rose by 2.83% [1] - The defense industry also saw significant inflow, with a net inflow of 5.713 billion yuan and a daily increase of 3.23% [1] - The electronics sector faced the largest net outflow, totaling 13.206 billion yuan, followed by the power equipment sector with an outflow of 7.206 billion yuan [1] Pharmaceutical and Biological Industry Performance - The pharmaceutical and biological sector declined by 0.42%, with a net capital outflow of 3.027 billion yuan [2] - Out of 478 stocks in this sector, 253 rose while 204 fell, with 2 stocks hitting the daily limit up [2] - The top three stocks with the highest net inflow were Sanbo Brain Science (1.42 billion yuan), Yunnan Baiyao (667.561 million yuan), and Innovation Medical (637.008 million yuan) [2] - The sector's outflow was led by Hengrui Medicine, which saw a net outflow of 372.7538 million yuan, followed by Xingqi Eye Medicine and Aidi Pharmaceutical with outflows of 208.3529 million yuan and 121.6946 million yuan respectively [3]

Market Overview - The medical services sector increased by 0.18% on January 21, with Nanmo Biology leading the gains [1] - The Shanghai Composite Index closed at 4116.94, up 0.08%, while the Shenzhen Component Index closed at 14255.12, up 0.7% [1] Top Gainers in Medical Services - Nanmo Biology (688265) closed at 49.79, up 7.01% with a trading volume of 20,000 shares and a transaction value of 98.02 million [1] - Hite Biology (300683) closed at 29.67, up 5.74% with a trading volume of 107,800 shares and a transaction value of 32.2 million [1] - Dean Diagnostics (300244) closed at 26.46, up 5.59% with a trading volume of 796,300 shares and a transaction value of 2.13 billion [1] - ST Zhongzhu (600568) closed at 2.64, up 5.18% with a trading volume of 376,500 shares and a transaction value of 9.81 million [1] - Tongce Medical (600763) closed at 46.51, up 4.99% with a trading volume of 198,600 shares and a transaction value of 911 million [1] Top Losers in Medical Services - Digital Human (920670) closed at 18.72, down 4.44% with a trading volume of 74,500 shares and a transaction value of 143 million [2] - Hongbo Pharmaceutical (301230) closed at 46.36, down 1.88% with a trading volume of 131,200 shares and a transaction value of 614 million [2] - Chengda Pharmaceutical (301201) closed at 41.39, down 1.76% with a trading volume of 36,600 shares and a transaction value of 153 million [2] Capital Flow in Medical Services - The medical services sector saw a net inflow of 50.51 million from institutional investors, while retail investors experienced a net outflow of 375 million [2] - The sector's overall capital flow indicates a strong interest from institutional and speculative investors, with retail investors pulling back [2][3] Notable Capital Inflows - Sanbo Brain Science (301293) had a net inflow of 91.48 million, representing 9.03% of its total capital [3] - Tongce Medical (600763) saw a net inflow of 83.46 million, accounting for 9.16% of its total capital [3] - BGI Genomics (300676) recorded a net inflow of 51.81 million, which is 8.37% of its total capital [3]

（文章来源：证券日报） 证券日报网讯 1月20日，三博脑科发布公告称，公司第三届董事会第十六次会议、2026年第一次临时股 东会审议通过了《关于部分募投项目结项并将节余募集资金永久补充流动资金及注销募集资金专户的议 案》。同意将"首都医科大学三博脑科医院建设项目"结项，同意注销募集资金专户，并将截至2025年12 月22日的节余募集资金7，027.72万元（含扣除手续费后的利息收入、现金管理收益等，实际金额以资 金转出当日募集资金专户余额为准）永久补充流动资金，用于公司日常生产经营及业务发展。公司于近 日办理完成了上述相关募集资金专用账户的注销手续，最终实际永久补充流动资金的节余募集资金金额 为7，029.71万元。本次涉及募集资金专户注销后，公司及北京三博脑科医院有限公司与保荐机构、监 管银行签订的募集资金四方监管协议随之终止。 ...

证券代码：301293 证券简称：三博脑科 公告编号：2026-004 三博脑科医院管理集团股份有限公司 关于注销部分募集资金专户的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、募集资金基本情况 经中国证券监督管理委员会证监许可〔2023〕534 号文《关于同意三博脑科 医院管理集团股份有限公司首次公开发行股票注册的批复》同意注册，并经深圳 证券交易所同意，三博脑科医院管理集团股份有限公司（以下简称"公司"）首次 公开发行人民币普通股（A 股）39,612,900 股，每股面值人民币 1.00 元，发行价 格为 29.60 元/股。本次发行募集资金总额 117,254.1840 万元；扣除发行费用（不 含增值税）后，募集资金净额为 106,163.91 万元，募集资金已于 2023 年 4 月 27 日划至公司指定账户，立信会计师事务所（特殊普通合伙）对公司本次公开发行 新股的资金到位情况进行了审验，并于2023年4月27日出具了"信会师报字[2023] 第 ZB10925 号"《验资报告》。公司已对募集资金采取了专户存储，并与专户银 行、保荐机构 ...

Group 1 - The core point of the article is that Sanbo Brain Science (301293.SZ) has confirmed that, apart from a previously completed intervention brain-computer interface surgery at its Fujian branch, there are no other surgeries currently being conducted within the group [1] Group 2 - The company has engaged with investors through an interactive platform to provide updates on its surgical activities [1] - The mention of the completed surgery indicates ongoing developments in the field of brain-computer interface technology [1] - The lack of additional surgeries may suggest a focus on consolidating existing operations before expanding further [1]